Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Complex injuries, including open wounds, fractures, and life-threatening conditions, require advanced medical care. Many of the treatments provided during the war were suboptimal, leaving patients in ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Bio announced the completion of all five planned Single Ascending Dose, SAD, cohorts and the commencement of the Multiple Ascending Dose ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...